Sagimet Biosciences (SGMT) Assets Average (2023 - 2026)

Sagimet Biosciences' Assets Average history runs 4 years deep, the most recent figure standing at $112.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 26.82% year-over-year to $112.1 million; the TTM figure through Mar 2026 stood at $112.1 million (down 26.82% YoY), while the FY2025 annual figure was $138.4 million, up 7.69% from the prior year.
• Assets Average for Q1 2026 stood at $112.1 million, down from $122.4 million in the prior quarter.
• The five-year high for Assets Average was $191.8 million in Q2 2024, with the low at $62.2 million in Q3 2023.
• The 4-year median for Assets Average is $141.8 million (2025), against an average of $137.4 million.
• The sharpest annual moves came in 2024 and 2025: Assets Average jumped 192.39% in 2024, then declined 26.93% in 2025.
• Sagimet Biosciences' Assets Average stood at $99.8 million in 2023, then soared by 67.82% to $167.5 million in 2024, then declined by 26.91% to $122.4 million in 2025, then dropped by 8.43% to $112.1 million in 2026.
• Business Quant data shows SGMT's Assets Average at $112.1 million in Q1 2026, $122.4 million in Q4 2025, and $132.9 million in Q3 2025.